Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-17

Clinical Trial Update: An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of nivolumab in advanced or metastatic cancers has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-17